Northern Gritstone leads £3 million seed funding round for Silvia Bio

By Public Technologies
  • Northern Gritstone led a £3 million seed funding round for Silvia Bio, a University of Sheffield biotechnology spinout.
  • Silvia Bio develops cell-profiling technology and manufacturing additives to help biopharmaceutical companies produce complex medicines more reliably at lower cost.
  • Other investors included Parkwalk Northern Universities Venture Fund, UK Innovation & Science Seed Fund, Wren Capital and angel investors.
  • The funding will enable Silvia Bio to triple its headcount, automate processes and accelerate development of licensable products.
  • Silvia Bio will also expand internationally and move into dedicated laboratory space at Sheffield's Innovation Centre.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northern Gritstone Ltd published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.